Adenovirus vaccine strains genetically engineered to express HIV-1 or HBV antigens for use as live recombinant vaccines.
Types 4 and 7 adenovirus are currently used as live, oral vaccines for the prevention of adenovirus respiratory disease in military recruits. These vaccine strains have been genetically engineered in order to express HIV-1 or HBV antigens in infected cells. A dog model was developed to evaluate the immunogenicity of these recombinant vaccines. Dogs inoculated with live adenovirus-HBV recombinant vaccine produced antibody against hepatitis B surface antigen.
Hung
P P
PP
Wyeth-Ayerst Research, Philadelphia, Pa.
Chanda
P K
PK
Natuk
R J
RJ
Mason
B B
BB
Chengalvala
M
M
Bhat
B M
BM
Molnar-Kimber
K L
KL
Dheer
S K
SK
Morin
J E
JE
Mizutani
S
S
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D004285:Dogs; D015488:HIV Antigens / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006511:Hepatitis B Antigens / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D006511:Hepatitis B Antigens; D006514:Hepatitis B Surface Antigens; D014614:Vaccines, Synthetic; D014765:Viral Vaccines